[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
March 26, 2008

Botox Risks Under Review

JAMA. 2008;299(12):1417. doi:10.1001/jama.299.12.1417-d

Patients treated with botulinum toxin type A (Botox and Botox Cosmetic) and botulinum toxin type B (Myobloc) for a variety of conditions have experienced adverse reactions, including respiratory failure and death, according to a February notice from the FDA.

The FDA is reviewing safety data from clinical trials of these products and postmarketing adverse event reports. The agency said there is no evidence of a defect in the product and that the reactions may be related to overdosing.

First Page Preview View Large
First page PDF preview
First page PDF preview
×